STAT+: Startups are turning to a century-old technology to fuel a resurgence in neuro drug development
Biotechs are used to turning to genetics as guideposts in developing new medications. Now, a small but growing number of startups are turning to a century-old technology found in hospitals and doctors’ offices across the country to find new clues for developing brain disorder treatments.
At least four biotechs — Athira Pharma, Alto Neuroscience, Beacon Biosignals, and Neumora Therapeutics — have integrated electroencephalograms, or EEGs, in their work. The tests use dozens of electrodes placed around a person’s head to measure brain waves, generally to diagnose epilepsy or sleep disorders, but these companies believe they could unveil new biomarkers for many other conditions.
Continue to STAT+ to read the full story…
